Conditions: Myeloid Leukemia, Chronic
Keywords: Imatinib resistant or intolerant chronic phase CML
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice daily. (BID)

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dasatinib intervention 2: dasatinib
Intervention descriptions: intervention 1: tablets, Oral, 100 mg, once daily intervention 2: tablets, Oral, 50 mg, twice daily

Protocol document: